尿激酶联合尤瑞克林治疗急性脑梗死的临床疗效研究

目的探讨尿激酶联合尤瑞克林静脉溶栓治疗急性脑梗死的临床疗效。方法将符合研究纳入标准的86例急性脑梗死患者随机分成观察组和对照组各43例,对照组在常规治疗基础上给予尿激酶静脉溶栓+生理盐水,观察组在常规治疗基础上给予尿激酶静脉溶栓联合尤瑞克林治疗。两组疗程均为2周,观察两组患者治疗前及治疗1周、2周后的血清生化指标(NSE、S-100β、MMP-9),两组患者治疗前及治疗2周后神经功能缺损(NIHSS)以及日常活动能力评分(ADL Barthel指数)、临床疗效及安全性。结果治疗7d后观察组血清NSE、S-100β以及MMP-9水平较对照组明显降低(P0.05),治疗14d后血清NSE和S-100β蛋白两组比较无明显差别(P0.05),但血清MMP-9比较仍有显著差异(P0.05);治疗前两组患者NIHSS评分和ADL Barthel指数差异无统计学意义(P0.05),治疗后观察组NIHSS评分明显低于对照组(P0.05),其ADL Barthel指数评分高于对照组;观察组临床总有效率明显高于对照组(P0.05),两组脑出血发生率差异无统计学意义(P0.05)。结论尤瑞克林联合尿激酶静脉溶栓较单用尿激酶治疗急性脑梗死疗效更有优势,值得临床推广,且并不增加脑出血风险。

Efficacy of Uribe brooklyn combined with Urokinase in treatment of patients with cerebral infarction

Objective To analyze the efficacy of Uribe brooklyn combined with Urokinase in improving the prognosis of patients with cerebral infarction. Methods Eighty-six patients with cerebral infarction were randomly divided into observation group （43 cases） and control group （43 cases）, patients in control group were treated with Urokinase, while others were treated with Uribe brooklyn and Urokinase. All patients were treated for 2 weeks. The neurological deficit score （NIHSS）, activities of daily living ability score （ADL）, biochemical indicator and efficacy of patients in both groups were observed. Results After the treatment, the NIHSS and ADL of patients in both groups were significantly improved （P〈0.05）. Scores of the observation group were significantly lower than that of the control group （P〈0.05）. After the treatment of 7d, the level of NSE, S-100β and MMP-9 in observation group were significantly lower than those of control group （P〈0.05）, while after the treatment of 14d, the level of MMP-9 in observation group were significantly lower than those of control group （P〈0.05）, and there were no significant difference on the level of NSE and S-100β between the two groups. The total effective rate of the observation group was significantly higher than that of the control group （P〈0.05）, while the rate of cerebral hemorrhage of the observation group was not significantly compare with that of control group （P〉0.05）. Conclusion Early treatment using Uribe Brooklyn and Urokinase can greatly improve the prognosis of patients with cerebral infarction.